Skip to main content
SNAP Update and Resources Actualización y recursos de SNAP

On November 1, 2025, the requirements to receive and apply to the Supplemental Nutrition Assistance Program (SNAP) benefits have changed. To see the new policies to request SNAP benefits, click here and/or call 211 for SNAP assistance. Learn more

El 1 de noviembre de 2025, cambiaron los requisitos para recibir y aplicar para los beneficios del Programa de Asistencia Nutricional Suplementaria (SNAP, por sus siglas en inglés). Para consultar las nuevas políticas para aplicar para los beneficios de SNAP, haz clic aquí o llama al 211 para obtener ayuda de SNAP. Aprende Más

Transportation Update Actualización de transporte

SafeRide Health (SRH) is the new provider for all NEMT rides to doctor appointments and pharmacy visits.

Depending on your needs, rides may include wheelchair-lift-equipped vehicles, stretcher vans, minivans, or ambulatory vans. Please let SRH know what type of ride you need when scheduling.

Learn more

SafeRide Health (SRH) es el nuevo proveedor de todos los servicios de transporte médico que no son de emergencia (NEMT, por sus siglas en inglés) hacia consultas médicas y farmacias.

Según tus necesidades, los servicios de transporte pueden incluir vehículos con elevador para sillas de ruedas, camionetas con camilla, minivans o camionetas ambulatorias. Por favor, informa a SRH qué tipo de transporte necesitas al programar tu traslado.

Obtenga más información AQUI

Prior Authorization Criteria for Ryoncil

Date: September 29, 2025

Attention: All Providers

Subject: Prior Authorization Criteria for Ryoncil

Effective date: October 1, 2025

Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that on October 1, 2025, Ryoncil, will become a benefit of Medicaid and CHIP. HHSC requires prior authorization for Ryoncil (procedure code J3402) for Medicaid and CHIP, effective for dates of service on or after November 1, 2025.

Ryoncil (remestemcel-L-rknd) is an allogenic bone marrow-derived mesenchymal stromal cell (MSC) therapy approved to treat steroid-refractory acute graft versus host disease (SR-aGVHD) in pediatric patients 2 months of age and older.

Prior Authorization Requirements

Prior authorization approval for an intravenous infusion of Ryoncil (remestemcel-L-rknd) J3402, will be considered when the following criteria are met:

  • Patient is at least 2 months or older;
  • Patient has a confirmed diagnosis of aGVHD (diagnosis code – D89.810) following an allogenic hematopoietic stem cell transplant;
  • Patient has no known hypersensitivity to dimethyl sulfoxide or porcine and bovine proteins; and
  • Patient’s aGVHD is steroid-refractory, as documented by the following:
  • Progression of acute GVHD within three days of consecutive treatment with 2 mg/kg/day of methylprednisolone or equivalent.
  • No signs of improvement within 7 days of therapy with 2mg/kg/day of methylprednisolone or equivalent treatment. 

Continuation Therapy

For continuation of Ryoncil therapy, providers must monitor the patient for the parameters listed below:

  • Patient has received Ryoncil for at least 28 days;
  • Patient has documentation of partial or mixed response to Ryoncil treatment; and
  • Patient is currently receiving or has received Ryoncil without any serious or life-threatening reactions.

Next step for providers: Providers should share this communication with their staff.

If you have any questions, please email Provider Relations at providerrelations@texaschildrens.org

For access to all provider alerts: www.texaschildrenshealthplan.org/provideralerts.